NCT03138499: A reported trial by Bristol-Myers Squibb
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03138499 |
|---|---|
| Title | Randomized, Open-label, Phase 3 Trial of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Participants With Relapsed Refractory or Ineligible for Autologous Stem Cell Transplant (ASCT) Advanced Stage Classical Hodgkin Lymphoma (CheckMate 812: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 812) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 26, 2017 |
| Completion date | Feb. 22, 2021 |
| Required reporting date | Feb. 22, 2022, midnight |
| Actual reporting date | Feb. 11, 2022 |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |